Apimeds Pharmaceuticals US Inc (APUS)

$4.00 -0.28 (-6.54%)
Market Cap 6.46M
Revenue (ttm) 0.00
Net Income (ttm) -6.00M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.06
Volume 38,200
Avg Vol 64,552
Day's Range N/A - N/A
Shares Out 1.51M
Stochastic %K 38%
Beta 0.16
Analysts Strong Buy
Price Target N/A

Company Profile

Apimeds Pharmaceuticals US, Inc. provides digital asset treasury solutions in bitcoin treasury infrastructure. The company was incorporated in 2020 and is based in Matawan, New Jersey. Apimeds Pharmaceuticals US, Inc. operates as a subsidiary of Inscobee., Inc.

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 848 201 5010
Address:
100 Matawan Rd, Suite 325, Matawan, United States
NetworkNewsWire
NetworkNewsWire Aug. 18 at 7:05 PM
InvestorNewsBreaks – $APUS Puts Institutional Infrastructure at the Center of Its Digital Strategy https://ibn.fm/7xcgA
0 · Reply
wellhellrex
wellhellrex Aug. 18 at 1:42 AM
$APUS $BATL $WTI $USO the message bots showed up late Friday and the APUS price spiked 100% in todays premarket at 3:45am. The bots showed up again late this afternoon. Shareholders Equity $106,448,541. Total shares outstanding 1,632,818. BV $65.19 per share. Be prepared for what's coming. https://www.sec.gov/ix?doc=/Archives/edgar/data/0001894525/000121390026090120/ea0300242-10q_apimeds.htm
1 · Reply
JimmyOcarri
JimmyOcarri Aug. 17 at 9:01 PM
$RXT $GS $CAKE $FGI $APUS cool
0 · Reply
JimmyOcarri
JimmyOcarri Aug. 17 at 7:45 PM
$KIDZ $NCT $STKH $FFAI $APUS Gemini
0 · Reply
michal360
michal360 Aug. 17 at 7:02 PM
$APUS Transparent milestone execution and regular engineering updates give investors high visibility into near-term protocol delivery.
0 · Reply
forexupdates
forexupdates Aug. 17 at 7:00 PM
$APUS Strong volume metrics and consistent liquidity support suggest resilience against broader market volatility.
0 · Reply
kleanthsi
kleanthsi Aug. 17 at 6:59 PM
$APUS Token holder growth and high engagement levels across channels highlight genuine organic support rather than short-term speculative noise.
0 · Reply
jacobs49
jacobs49 Aug. 17 at 6:58 PM
$APUS $APUS is demonstrating impressive underlying momentum, supported by a clear development vision and strong community execution.
0 · Reply
robertphiliprdx
robertphiliprdx Aug. 17 at 6:56 PM
$APUS Clean documentation, verifiable codebases, and compliance-conscious development make it a prime candidate for wider ecosystem integration.
0 · Reply
robertphiliprdx
robertphiliprdx Aug. 17 at 6:56 PM
$APUS Strategic roadmap milestones are being met on schedule, reflecting a focused leadership team capable of navigating shifting market conditions.
0 · Reply
Latest News on APUS
NILA Token Now Available to Eligible U.S. Users on Webot, a Licensed U.S. Cryptocurrency Exchange

Aug 3, 2026, 9:00 AM EDT - 16 days ago

NILA Token Now Available to Eligible U.S. Users on Webot, a Licensed U.S. Cryptocurrency Exchange

Apimeds Pharmaceuticals US Inc trading resumes

2026-07-30T13:55:40.000Z - 20 days ago

Apimeds Pharmaceuticals US Inc trading resumes

Apimeds Pharmaceuticals US Inc trading halted, volatility trading pause

2026-07-30T13:50:28.000Z - 20 days ago

Apimeds Pharmaceuticals US Inc trading halted, volatility trading pause

MindWave Innovations Inc., a Wholly Owned Subsidiary of Apimeds Pharmaceuticals US, Inc., Announces MindChain: World's First Fully Insured Blockchain, Launching in October

Jul 28, 2026, 8:30 AM EDT - 22 days ago

MindWave Innovations Inc., a Wholly Owned Subsidiary of Apimeds Pharmaceuticals US, Inc., Announces MindChain: World's First Fully Insured Blockchain, Launching in October

For Second Straight Year, American Public University System (APUS) Earns Great Place to Work® Certification

Jun 8, 2026, 9:00 AM EDT - 2 months ago

For Second Straight Year, American Public University System (APUS) Earns Great Place to Work® Certification

APEI

Apimeds Pharmaceuticals US Settles with Inscobee; Merger Proceeds, $100 Million PIPE Financing to Close, and Lōkahi Therapeutics to Advance Apitox Program

May 5, 2026, 2:07 PM EDT - 3 months ago

Apimeds Pharmaceuticals US Settles with Inscobee; Merger Proceeds, $100 Million PIPE Financing to Close, and Lōkahi Therapeutics to Advance Apitox Program

Apimeds Pharmaceuticals US Annual report: Q4 2025

May 4, 2026, 7:00 AM EDT - 3 months ago

Apimeds Pharmaceuticals US Annual report: Q4 2025

Inscobee, Apimeds Korea deliver action by written consent to remove directors

2026-03-25T11:21:47.000Z - 5 months ago

Inscobee, Apimeds Korea deliver action by written consent to remove directors

Apimeds Pharma US reports material breach of merger agreement by Inscobee

2026-03-24T12:35:14.000Z - 5 months ago

Apimeds Pharma US reports material breach of merger agreement by Inscobee

Apimeds Pharmaceuticals US Inc. Announces Material Breach of Merger Agreement by Inscobee Inc. (KS:006490) and Apimeds Inc.; Prepares Filing Emergency Action in Delaware Court of Chancery

Mar 24, 2026, 8:30 AM EDT - 5 months ago

Apimeds Pharmaceuticals US Inc. Announces Material Breach of Merger Agreement by Inscobee Inc. (KS:006490) and Apimeds Inc.; Prepares Filing Emergency Action in Delaware Court of Chancery

Apimeds Pharmaceuticals confirms FDA Type C meeting for osteoarthritis candidate

2026-02-11T21:55:14.000Z - 6 months ago

Apimeds Pharmaceuticals confirms FDA Type C meeting for osteoarthritis candidate

Apimeds Pharmaceuticals and Lōkahi Therapeutics Announce FDA Type C Meeting Scheduled for LT‑100 (Apitox)

Feb 11, 2026, 4:51 PM EST - 6 months ago

Apimeds Pharmaceuticals and Lōkahi Therapeutics Announce FDA Type C Meeting Scheduled for LT‑100 (Apitox)

Apimeds Pharmaceuticals and MindWave Innovations Announce Closing of $100MM PIPE Financing and Activation of 1,000 Bitcoin to Power AI-Driven Yield Generation Strategy

Dec 10, 2025, 9:58 AM EST - 8 months ago

Apimeds Pharmaceuticals and MindWave Innovations Announce Closing of $100MM PIPE Financing and Activation of 1,000 Bitcoin to Power AI-Driven Yield Generation Strategy

Apimeds Pharmaceuticals US Inc trading resumes

2025-12-01T14:50:10.000Z - 9 months ago

Apimeds Pharmaceuticals US Inc trading resumes

Apimeds Pharmaceuticals, MindWave Innovations announce merger

2025-12-01T14:35:27.000Z - 9 months ago

Apimeds Pharmaceuticals, MindWave Innovations announce merger

Apimeds and MindWave Announce Merger, Integrating Biotech Growth with AI-Driven Digital Treasury Yield Generation Backed by $100M PIPE

Dec 1, 2025, 9:25 AM EST - 9 months ago

Apimeds and MindWave Announce Merger, Integrating Biotech Growth with AI-Driven Digital Treasury Yield Generation Backed by $100M PIPE

Apimeds Pharmaceuticals US Inc trading halted, news pending

2025-12-01T14:05:31.000Z - 9 months ago

Apimeds Pharmaceuticals US Inc trading halted, news pending

Apimeds Pharmaceuticals US Quarterly report: Q3 2025

Nov 12, 2025, 7:00 AM EST - 10 months ago

Apimeds Pharmaceuticals US Quarterly report: Q3 2025

Apimeds Brings ai² Futures Lab™ to the Palouse — Partnering with the University of Idaho to Shape the Future of Biotech Innovation

Nov 10, 2025, 10:00 AM EST - 10 months ago

Apimeds Brings ai² Futures Lab™ to the Palouse — Partnering with the University of Idaho to Shape the Future of Biotech Innovation

Apimeds Pharmaceuticals expands AI Futures Lab program

2025-10-14T09:30:18.000Z - 11 months ago

Apimeds Pharmaceuticals expands AI Futures Lab program

Apimeds Pharmaceuticals says “I love my Ducks” with new ai² Futures Lab™ Program collaboration with the University of Oregon's Lundquist College of Business

Oct 14, 2025, 3:02 AM EDT - 11 months ago

Apimeds Pharmaceuticals says “I love my Ducks” with new ai² Futures Lab™ Program collaboration with the University of Oregon's Lundquist College of Business

Apimeds Expands ai² Future Labs Program to Include University of San Diego Students in Biotech Business Development

Sep 15, 2025, 6:24 PM EDT - 1 year ago

Apimeds Expands ai² Future Labs Program to Include University of San Diego Students in Biotech Business Development

Apimeds Pharmaceuticals issues statement on FDA draft guidance for pain program

2025-09-12T09:20:11.000Z - 1 year ago

Apimeds Pharmaceuticals issues statement on FDA draft guidance for pain program

Apimeds Welcomes FDA Draft Guidance as Catalyst for Advancing Apitox Non-Opioid Pain Program

Sep 11, 2025, 9:54 PM EDT - 1 year ago

Apimeds Welcomes FDA Draft Guidance as Catalyst for Advancing Apitox Non-Opioid Pain Program

Apimeds Pharmaceuticals US, Inc. Partners with University of Alabama to Advance Biotech Business Development via ai² Future Labs

Aug 25, 2025, 2:11 PM EDT - 1 year ago

Apimeds Pharmaceuticals US, Inc. Partners with University of Alabama to Advance Biotech Business Development via ai² Future Labs

Apimeds Expands Leadership Team with Dr. Susan Kramer to Lead Product Development and Brian Peters to Lead its ai² Division

Jul 15, 2025, 5:34 PM EDT - 1 year ago

Apimeds Expands Leadership Team with Dr. Susan Kramer to Lead Product Development and Brian Peters to Lead its ai² Division

Apimeds Pharmaceuticals US Slides: Corporate Presentation

Jul 15, 2025, 7:00 AM EDT - 1 year ago

Apimeds Pharmaceuticals US Slides: Corporate Presentation

Apimeds Pharmaceuticals US, Inc. Announces Closing of Initial Public Offering

May 12, 2025, 5:14 PM EDT - 1 year ago

Apimeds Pharmaceuticals US, Inc. Announces Closing of Initial Public Offering

Apimeds Pharmaceuticals US, Inc. Announces Pricing of Initial Public Offering

May 8, 2025, 5:00 PM EDT - 1 year ago

Apimeds Pharmaceuticals US, Inc. Announces Pricing of Initial Public Offering

NetworkNewsWire
NetworkNewsWire Aug. 18 at 7:05 PM
InvestorNewsBreaks – $APUS Puts Institutional Infrastructure at the Center of Its Digital Strategy https://ibn.fm/7xcgA
0 · Reply
wellhellrex
wellhellrex Aug. 18 at 1:42 AM
$APUS $BATL $WTI $USO the message bots showed up late Friday and the APUS price spiked 100% in todays premarket at 3:45am. The bots showed up again late this afternoon. Shareholders Equity $106,448,541. Total shares outstanding 1,632,818. BV $65.19 per share. Be prepared for what's coming. https://www.sec.gov/ix?doc=/Archives/edgar/data/0001894525/000121390026090120/ea0300242-10q_apimeds.htm
1 · Reply
JimmyOcarri
JimmyOcarri Aug. 17 at 9:01 PM
$RXT $GS $CAKE $FGI $APUS cool
0 · Reply
JimmyOcarri
JimmyOcarri Aug. 17 at 7:45 PM
$KIDZ $NCT $STKH $FFAI $APUS Gemini
0 · Reply
michal360
michal360 Aug. 17 at 7:02 PM
$APUS Transparent milestone execution and regular engineering updates give investors high visibility into near-term protocol delivery.
0 · Reply
forexupdates
forexupdates Aug. 17 at 7:00 PM
$APUS Strong volume metrics and consistent liquidity support suggest resilience against broader market volatility.
0 · Reply
kleanthsi
kleanthsi Aug. 17 at 6:59 PM
$APUS Token holder growth and high engagement levels across channels highlight genuine organic support rather than short-term speculative noise.
0 · Reply
jacobs49
jacobs49 Aug. 17 at 6:58 PM
$APUS $APUS is demonstrating impressive underlying momentum, supported by a clear development vision and strong community execution.
0 · Reply
robertphiliprdx
robertphiliprdx Aug. 17 at 6:56 PM
$APUS Clean documentation, verifiable codebases, and compliance-conscious development make it a prime candidate for wider ecosystem integration.
0 · Reply
robertphiliprdx
robertphiliprdx Aug. 17 at 6:56 PM
$APUS Strategic roadmap milestones are being met on schedule, reflecting a focused leadership team capable of navigating shifting market conditions.
0 · Reply
Alex0989
Alex0989 Aug. 17 at 6:54 PM
$APUS Delivering updates and technical upgrades on schedule builds ongoing trust with both retail participants and institutional observers.
0 · Reply
Alex0989
Alex0989 Aug. 17 at 6:54 PM
$APUS The core infrastructure shows consistent uptime, well-structured tokenomics, and clear utility that sets a strong foundation for long-term scalability.
0 · Reply
wellhellrex
wellhellrex Aug. 17 at 3:57 PM
$APUS Shareholders Equity $106,448,541. Total shares outstanding 1,632,818. BV $65.19 per share. https://www.sec.gov/ix?doc=/Archives/edgar/data/0001894525/000121390026090120/ea0300242-10q_apimeds.htm $RIOT $MARA
0 · Reply
Komba123
Komba123 Aug. 17 at 12:27 PM
$APUS what happened here?
0 · Reply
CoffeeRocks
CoffeeRocks Aug. 17 at 11:37 AM
$MOBX $APUS $LASE $MNTS Deep deep bottoms
0 · Reply
TA_Kongen
TA_Kongen Aug. 17 at 11:23 AM
$APUS Nice amount of bots here lmfao. Ban.
0 · Reply
setforyou
setforyou Aug. 17 at 10:51 AM
$APUS short scalp
0 · Reply
UltraVolatileBob
UltraVolatileBob Aug. 17 at 10:51 AM
$APUS Catalyst?
0 · Reply
ohyesarooni
ohyesarooni Aug. 15 at 7:17 PM
$GDC 10Q Friday night 7500 bitcoin plus cash, 4 mil OS, $2 SP $120 BV ? what? NFA $KUST $APUS $YYGH
1 · Reply
Alex0989
Alex0989 Aug. 15 at 5:14 PM
$APUS $APUS is quietly becoming a powerhouse.
0 · Reply
michal360
michal360 Aug. 15 at 5:10 PM
$APUS The momentum behind $APUS is undeniable right now. If you aren't paying attention, you're missing out!
1 · Reply
forexupdates
forexupdates Aug. 15 at 5:08 PM
What stands out about $APUS is the focus on scalable execution over pure hype. Real AI integration requires high performance, and $APUS delivers.
0 · Reply